An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumours (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Trial Profile

An Open-Label, Multicenter Phase 1b/2 Study of E7050 in Combination With E7080 in Subjects With Advanced Solid Tumours (Dose Escalation) and in Subjects With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jun 2016

At a glance

  • Drugs Golvatinib (Primary) ; Lenvatinib (Primary)
  • Indications Glioblastoma; Malignant melanoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 02 Jun 2016 Planned End Date changed to 1 Dec 2016.
    • 21 Nov 2014 Results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 18 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top